ClinicalTrials.gg
CompletedNCT02965404Updated Oct 26, 2017

A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children

A Phase 1 interventional study of Investigational live attenuated varicella vaccine and control live attenuated varicella vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 1 Year to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
1 Year to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Planned enrollment
24th of 36
270 · median 404
Started
2016
with 1 other
Phase 1
4 of 36
none open now
Registered
21st of 36
by date
Lead sponsor
11 of 36
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 24th largest by planned enrollment, is one of 2 that started in 2016, is one of 4 in phase 1, and was the 21st registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 1 Year to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of a live attenuated varicella vaccine in healthy adults, adolescents, and children.

Read the detailed description

This study is a randomized, blind, single-center, controlled phase I clinical trial. The purpose of this study is to evaluate the safety of a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The positive control is a commercialized live attenuated varicella vaccine manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP), and the negative control is diluent of lyophilized vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are healthy, and will be randomly assigned into experimental group, positive control group, or negative control group in the ratio 1:1:1.

03

Conditions studied

  • Varicella

Browse trials for

Keywords

  • live attenuated varicella vaccine
  • safety
  • adult
  • adolescent
  • child
04

Who can participate

Ages eligible
1 Year to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer between 1 - 49 years old;
  • Proven legal identity;
  • Guardian(s) of the volunteer and/or volunteers themselves should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study;

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination with varicella vaccine or with history of varicella zoster virus (VZV) infection;
  • Axillaty temperature > 37.0 °C;
  • Breast feeding, pregnant, or expected to conceive during the period of this trial;
  • History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;
  • History of epilepsy, seizures or convulsions, or a family history of mental illness;
  • disease or immunodeficiency;
  • Severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Receipt of any of the following products:

    1. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
    2. Any within 1 month prior to study entry;
    3. Any blood product, , hormone, or other medicine(s) within 30 days prior to study entry;
  • Any significant abnormity of heart, lung, skin, or pharynx;
  • Any of the pre-immune test results of the following indexes of laboratory tests showed abnormity:

    1. Blood routine examinations: (Hb), white blood cells (WBC) count;
    2. Blood biochemistry detections: alanine transferase (), total , blood urea nitrogen (BUN), creatinine;
    3. Urine routine tests: urine protein, urine glucose, urine erythrocyte
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    * Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0; * Intervention: investigational live attenuated varicella vaccine.

    Biological: Investigational live attenuated varicella vaccine

  • Active comparator
    Positive Control Group

    * Single intramuscular injection of the control vaccine (0.5 ml) on Day 0; * Intervention: control live attenuated varicella vaccine.

    Biological: control live attenuated varicella vaccine

  • Sham comparator
    Negative Control Group

    * Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0; * Intervention: diluent of lyophilized vaccine.

    Biological: diluent of lyophilized vaccine

Interventions

  • The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

  • Biologicalcontrol live attenuated varicella vaccine

    The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)

  • Biologicaldiluent of lyophilized vaccine

    The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology

06

What researchers measure

Primary outcomes

  1. The incidences of adverse events (AEs) of each group

    AEs occurred within 30 days after injection will be collected.

    Time frame: 30 days

Secondary outcomes

  1. The incidences of abnormal results of lab tests

    Cases of abnormal results of laboratory tests will be collected.

    Time frame: 30 days

  2. The incidences of serious adverse events (SAEs) of each group

    SAEs occurred within 30 days after injection will be collected.

    Time frame: 30 days

07

Study locations

1 site
  • Xiangcheng County Center for Disease Control and Prevention
    Xuchang, Henan 461700, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of May 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2016
First posted
Nov 16, 2016
Start
Apr 2016
Primary completionActual
May 2016
CompletionActual
Aug 2016
Last update
Oct 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02965404
Responsible party
Sponsor
First posted
Nov 16, 2016
Start date
Apr 2016
Primary completion
May 2016
Completion
Aug 2016
Last update
Oct 26, 2017

Study contacts

Shengli Xia
principal investigator · Henan Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion